suvorexant Belsomra
Selected indexed studies
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (Transl Psychiatry, 2025) [PMID:40555730]
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. (Ann Neurol, 2023) [PMID:36897120]
- Suvorexant (Belsomra) for insomnia. (Med Lett Drugs Ther, 2015) [PMID:25719996]
_Worker-drafted node — pending editorial review._
Connections
suvorexant Belsomra is a side effect of
Sources
- Insomnia Management: A Review and Update. (2023) pubmed
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (2025) pubmed
- Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. (2020) pubmed
- Suvorexant. (2006) pubmed
- Suvorexant. (2012) pubmed
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. (2023) pubmed
- Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial. (2024) pubmed
- Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. (2016) pubmed
- Orexin Receptor Antagonists and Insomnia. (2022) pubmed
- Suvorexant (Belsomra) for insomnia. (2015) pubmed